Atossa Therapeutics Common Stock to Begin Trading with Stapled Contingent Value Rights After Close of Business TodayPRNewsWire · 5 days ago
Atossa Therapeutics Executes Contingent Value Rights Agreement Providing Shareholders Participation in Potential Priority Review Voucher ValuePRNewsWire · Oct 9, 2026
Atossa Therapeutics Announces Plan to Issue Stapled CVR for Shareholders Tied to Potential Rare Pediatric Disease Priority Review VoucherPRNewsWire · Sep 29, 2026
Atossa Therapeutics CEO Dr. Steven Quay to Participate in ARDD 2026 Panel on Clinical Trials and Regulatory Pathways for Diseases of AgingPRNewsWire · Sep 24, 2026
Atossa Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate UpdatePRNewsWire · Aug 7, 2026
Atossa Therapeutics Announces Publication of Novel (Z)-Endoxifen-Related Compounds Demonstrating Potent Anti-Cancer Activity in ER-Positive Breast CancerPRNewsWire · Jul 28, 2026Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing innovative medicines. Their primary focus lies in addressing unmet medical needs in women's oncology, especially breast cancer, along with other conditions, within the United States. The company's flagship therapeutic candidate is oral (Z)-endoxifen.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 7, 2026 | -$1.02 | -$0.95 | Beat |
| May 8, 2026 | -$1.22 | -$1.11 | Beat |
| Mar 25, 2026 | -$1.14 | -$1.19 | Miss |
| Nov 12, 2025 | -$0.98 | -$1.05 | Miss |
| Aug 12, 2025 | -$0.90 | -$1.05 | Miss |
| May 13, 2025 | -$0.06 | -$0.75 | Miss |